What is the typical dosing for CagriSema?

Doses from clinical trials. Common doses observed in research: Semaglutide 2.4mg + Cagrilintide 2.4mg weekly. Duration: Long-term use expected. Administration: Subcutaneous injection weekly.

Weight Loss

CagriSema

Also known as: Semaglutide + Cagrilintide

Clinical Trials

Category: Weight Loss
FDA Status: Not FDA Approved
Clinical Status: NDA Submitted (Dec 18, 2025) - FDA decision expected Q4 2026. First once-weekly combination of GLP-1 and amylin analogues for weight management.
Administration: Subcutaneous injection weekly
Typical Dose: Limited community data available
Frequency: See research protocols
Duration: Long-term use expected

Also Known As

Semaglutide + Cagrilintide

Mechanism of Action

Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1.

Research Summary

Phase 3 REDEFINE 1 trial showed 22.7% weight loss at 68 weeks, significantly outperforming semaglutide alone (15.8%). NDA submitted to FDA in December 2025. If approved, expected to become the leading obesity treatment.

Trial Progress:Preclinical

Pre

III

FDA

Dosing Information

Human Trials·Human studies conducted, not FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Doses from clinical trials

Doses from Studies

Semaglutide 2.4mg + Cagrilintide 2.4mg weekly

Clinical Trial Data - Phase 3 Clinical Trials ↗

Duration

Long-term use expected

Administration

Subcutaneous injection weekly

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

Follow specific peptide protocol

Food Recommendation

Take on empty stomach

Why This Timing?

GH-related peptides work best on an empty stomach to maximize growth hormone release.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Nausea
●Vomiting
●Diarrhea
●Constipation
●GI events (72-80% vs 34-40% placebo)
●Higher GI effects than semaglutide alone
●Investigational - not yet approved

References

Research This Peptide Further

PubMed ClinicalTrials.gov FDA.gov

Frequently Asked Questions

What does CagriSema do?

A combination of semaglutide and cagrilintide (amylin analog). The most effective weight loss drug candidate, showing 22.7% body weight reduction in Phase 3 trials - superior to any single-agent GLP-1.

How does CagriSema work?

Combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). Amylin adds satiety signaling and slows gastric emptying through different pathways than GLP-1.

Is CagriSema FDA approved?

No, CagriSema is not currently FDA approved. Current status: NDA Submitted (Dec 18, 2025) - FDA decision expected Q4 2026. First once-weekly combination of GLP-1 and amylin analogues for weight management.

What are the side effects of CagriSema?

Reported side effects include: Nausea, Vomiting, Diarrhea, Constipation, GI events (72-80% vs 34-40% placebo). Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of CagriSema?

Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Subcutaneous injection weekly. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with CagriSema or used in similar applications.

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

Orforglipron

FDA

An oral non-peptide GLP-1 receptor agonist. FDA approved April 1, 2026 under the brand name Foundayo - the first daily oral GLP-1 pill for weight loss. Distribution began April 6, 2026. FDA subsequently requested additional post-approval safety data.

Weight Loss